Skip to NavigationSkip to content


Novartis signs $90m deal with Oxford BioMedica

Novartis image

UK-based biotech Oxford BioMedica is working with Novartis in a transformational deal for the firm worth $90 million to develop and manufacture cancer treatments.

This new collaboration builds upon a previous development contract between the firms dating back to May last year, which introduced a £4m pact centering around viral lentivectors.

Cancer Vaccines

Cancer Vaccines

Novartis buys into Transgene's lung cancer candidate

French biotech company Transgene has signed a deal with Novartis for the future development and marketing of its potential lung cancer treatment.

Novartis has paid $10 million to gain exclusive rights to the targeted immunotherapy product, TG4010, which is set to enter a crucial phase IIb/III clinical trial by the end of 2010.

The deal could give Transgene a further €700 million ($950 million) if the drug reaches the market, plus royalties on sales.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches